Prevention and treatment of cancer-associated thrombosis in France: A national survey among vascular disease and supportive care specialists.
Fiche publication
Date publication
octobre 2017
Journal
Journal de medecine vasculaire
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MAYEUR Didier
Tous les auteurs :
Mahé I, Scotté F, Rey JB, Elalamy I, Lamblin A, Mayeur D, Pernod G,
Lien Pubmed
Résumé
Long-term use of low-molecular-weight heparins (LMWH) for the treatment of cancer-associated thrombosis (CAT) has been well-established. Conversely, the use of thromboprophylaxis in patients with cancer remains controversial in the absence of homogeneous guidelines. Our aim was to assess the awareness of treatment guidelines and the management of patients with CAT in daily clinical practice.
Mots clés
Cancer, Héparine de bas poids moléculaire, Low-molecular-weight heparin, Maladie veineuse thromboembolique, Recommandations, Treatment guidelines, Venous thromboembolism
Référence
J Med Vasc. 2017 10;42(5):255-262